Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477982 | 1.00 | EDNRB (0.38) | EDNRBEDNRAHDAC9KIF11MEN1 | |
| SCHEMBL28476847 | 0.89 | KIF11 (0.37) | EDNRBEDNRAHDAC9KIF11 | |
| SCHEMBL28476843 | 0.89 | KIF11 (0.37) | EDNRBEDNRAHDAC9KIF11 | |
| SCHEMBL1695321 | 0.86 | HDAC9 (0.40) | EDNRBEDNRAHDAC9KIF11MEN1 | |
| SCHEMBL4630185 | 0.86 | HDAC9 (0.40) | EDNRBEDNRAHDAC9KIF11MEN1 | |
| SCHEMBL4879031 | 0.81 | KIF11 (0.39) | EDNRBEDNRAHDAC9KIF11MEN1 | |
| SCHEMBL5873449 | 0.76 | HTR2A (0.34) | EDNRBEDNRAKIF11 | |
| SCHEMBL19644421 | 0.70 | MEN1 (0.40) | MEN1 | |
| SCHEMBL27956103 | 0.70 | HDAC9 (0.43) | EDNRBEDNRAHDAC9KIF11MEN1 | |
| SCHEMBL3732088 | 0.70 | HDAC9 (0.43) | EDNRBEDNRAHDAC9KIF11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011048607-A1 | PROCESSES FOR THE PREPARATION OF SOLIFENACIN OR A SALT THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-04-28 | — | — | WO | disclosed |
| CN-101501001-A | Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline | TEVA PHARMA (IL) | 2009-08-05 | — | — | CN | disclosed |
| US-20080091023-A1 | Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline | TEVA PHARMACEUTICALS USA, INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091023-A1 | Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline | SUCNR1, OPRL1, CHRM1 | EDNRB 1616/4885EDNRA 978/4885HDAC9 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.